Compare with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SANOFI INDIA ALKEM LABORATORIES/
SANOFI INDIA
 
P/E (TTM) x 23.3 42.3 55.2% View Chart
P/BV x 5.6 8.6 65.4% View Chart
Dividend Yield % 0.9 1.0 85.1%  

Financials

 ALKEM LABORATORIES   SANOFI INDIA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
SANOFI INDIA
Dec-18
ALKEM LABORATORIES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs2,7206,840 39.8%   
Low Rs1,6604,630 35.9%   
Sales per share (Unadj.) Rs697.91,203.1 58.0%  
Earnings per share (Unadj.) Rs96.1165.3 58.2%  
Cash flow per share (Unadj.) Rs117.3209.9 55.9%  
Dividends per share (Unadj.) Rs25.0084.00 29.8%  
Dividend yield (eoy) %1.11.5 77.9%  
Book value per share (Unadj.) Rs515.2963.6 53.5%  
Shares outstanding (eoy) m119.5723.03 519.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.14.8 65.8%   
Avg P/E ratio x22.834.7 65.7%  
P/CF ratio (eoy) x18.727.3 68.3%  
Price / Book Value ratio x4.36.0 71.4%  
Dividend payout %26.050.8 51.2%   
Avg Mkt Cap Rs m261,879132,078 198.3%   
No. of employees `00014.33.3 434.1%   
Total wages/salary Rs m15,0554,068 370.1%   
Avg. sales/employee Rs Th5,822.68,393.8 69.4%   
Avg. wages/employee Rs Th1,050.51,232.4 85.2%   
Avg. net profit/employee Rs Th802.01,153.0 69.6%   
INCOME DATA
Net Sales Rs m83,44427,708 301.2%  
Other income Rs m1,042897 116.2%   
Total revenues Rs m84,48628,605 295.4%   
Gross profit Rs m14,7346,235 236.3%  
Depreciation Rs m2,5281,027 246.1%   
Interest Rs m6517 9,294.3%   
Profit before tax Rs m12,5986,098 206.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,1052,292 48.2%   
Profit after tax Rs m11,4933,806 302.0%  
Gross profit margin %17.722.5 78.5%  
Effective tax rate %8.837.6 23.3%   
Net profit margin %13.813.7 100.3%  
BALANCE SHEET DATA
Current assets Rs m54,96015,922 345.2%   
Current liabilities Rs m32,4336,235 520.2%   
Net working cap to sales %27.035.0 77.2%  
Current ratio x1.72.6 66.4%  
Inventory Days Days8064 125.0%  
Debtors Days Days7221 345.8%  
Net fixed assets Rs m32,7107,539 433.9%   
Share capital Rs m239230 104.0%   
"Free" reserves Rs m61,36821,962 279.4%   
Net worth Rs m61,60722,192 277.6%   
Long term debt Rs m1,5920-   
Total assets Rs m99,43329,839 333.2%  
Interest coverage x20.4872.1 2.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.9 90.4%   
Return on assets %12.212.8 95.6%  
Return on equity %18.717.2 108.8%  
Return on capital %21.027.5 76.2%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,0617,587 211.7%   
Fx outflow Rs m2,4837,145 34.8%   
Net fx Rs m13,578442 3,072.0%   
CASH FLOW
From Operations Rs m5,8513,739 156.5%  
From Investments Rs m-7,414-731 1,014.2%  
From Financial Activity Rs m792-1,972 -40.1%  
Net Cashflow Rs m-7311,036 -70.6%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 33.1 14.4 229.9%  
FIIs % 0.0 14.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.5 -  
Shareholders   68,381 15,184 450.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PIRAMAL ENTERPRISES  GSK PHARMA  FRESENIUS KABI ONCO.  DR. REDDYS LAB  ABBOTT INDIA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 450 Points Higher; BPCL Jumps 4%(09:30 am)

Asian share markets are trading on a mixed note today as stocks extended the global rally as a halt in a recent bond markets sell-off eased investor nerves and lifted riskier assets.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 2, 2021 10:18 AM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - SUVEN LIFE SCIENCES COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS